[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pemphigus-foliaceus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pemphigus-foliaceus":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100266897",false,"NCT02753777","Autoimmune Blistering Diseases Study","Prevalence and Clinical Severity of Autoimmune Blistering Diseases","AIBD","Inclusion Criteria:\n\n* Gender\u002FAge: Males or females above 18 years old\n* Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid\n* Subjects able to give informed consent\n\nExclusion Criteria:\n\n* Patients who are under age 18 years.\n* Patients without pemphigus or pemphigoid diseases\n* Penn employees\n* Penn students\n* Cognitively impaired persons","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","3 Years","OBSERVATIONAL","Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.",[25,26,27],"Pemphigus Vulgaris","Pemphigus Foliaceus","Bullous Pemphigoid","RECRUITING","2026-03-24",{"date":31,"type":32},"2026-03-30","ACTUAL",{"date":34,"type":4},"2016-04",{"date":36,"type":20},"2030-01-02",{"name":38,"class":39},"University of Pennsylvania","OTHER",3,""]